Sodium–glucose cotransporter 2 (SGLT2) inhibitors are novel oral glucose-lowering agents originally designed for patients with type 2 diabetes mellitus to improve glycaemic control. This evidence concerns the gene SLC5A2 and diabetes mellitus.